Download PDF
Drug Res (Stuttg) 2021; 71(05): 265-274
DOI: 10.1055/a-1336-2371
Original Article

Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis

Timotius Ivan Hariyanto
1   Faculty of Medicine, Pelita Harapan University, Karawaci, Tangerang, Indonesia
,
Willie Hardyson
1   Faculty of Medicine, Pelita Harapan University, Karawaci, Tangerang, Indonesia
,
Andree Kurniawan
2   Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Karawaci, Tangerang, Indonesia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Currently, the data regarding the effectiveness and safety of tocilizumab as treatment for COVID-19 infection is still conflicting. This study aims to give clear evidence regarding the potential benefit and safety of tocilizumab in improving the outcome of COVID-19 patients.

Methods We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until November 1st, 2020. All articles published on COVID-19 and tocilizumab were retrieved. Statistical analysis was done using Review Manager 5.4 software.

Results A total of 38 studies with a total of 13 412 COVID-19 patients were included in our analysis. Our meta-analysis showed that tocilizumab treatment is associated with reduction of mortality rate from COVID-19 [OR 0.54 (95% CI 0.42–0.71), p<0.00001, I 2=79%, random-effect modelling], but did not alter the severity of COVID-19 [OR 1.05 (95% CI 0.92–1.20), p=0.47, I 2=84%, random-effect modelling] and length of hospital stay [Mean Difference 1.77 days (95% CI −0.61–4.14 days), p=0.15, I 2=97%, random-effect modelling]. Tocilizumab also does not associated with serious adverse events compared with standard of care treatment [OR 0.91 (95% CI 0.71–1.15), p=0.42, I 2=46%, random-effect modelling].

Conclusion Our study does not support the routine use of tocilizumab for COVID-19 patients. Future studies should focus more on other potential therapies for COVID-19 patients.

Key words

coronavirus disease 2019 - COVID-19 - tocilizumab - immunomodulator - treatment


Publication History

Received: 25 November 2020

Accepted: 07 December 2020

Article published online:
05 January 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Kwenandar F, Japar KV, Damay V. et al. Coronavirus disease 2019 and cardiovascular system: A narrative review. Int J Cardiol Heart Vasc 2020; 29: 100557
    CrossrefPubMedSearch in Google Scholar
  • 2 Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr 2020; 10.1016/j.dsx.2020.07.054
    CrossrefPubMedSearch in Google Scholar
  • 3 Hariyanto TI, Kurniawan A. Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr 2020; 14: 1429-1430
    CrossrefPubMedSearch in Google Scholar
  • 4 Hariyanto TI, Kurniawan A. Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Transfus Apher Sci 2020; Aug 28 102926
    CrossrefPubMedSearch in Google Scholar
  • 5 Biggioggero M, Crotti C, Becciolini A. et al. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther 2018; 13: 57-70
    CrossrefPubMedSearch in Google Scholar
  • 6 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6: e1000097
    CrossrefPubMedSearch in Google Scholar
  • 7 Margulis AV, Pladevall M, Riera-Guardia N. et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol 2014; 6: 359-368
    CrossrefPubMedSearch in Google Scholar
  • 8 Sterne JAC, Savović J, Page MJ. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898
    CrossrefPubMedSearch in Google Scholar
  • 9 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101
    CrossrefPubMedSearch in Google Scholar
  • 10 Egger M, Davey SG, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
    CrossrefPubMedSearch in Google Scholar
  • 11 Wan X, Wang W, Liu J. et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135
    CrossrefPubMedSearch in Google Scholar
  • 12 Campochiaro C, Della-Torre E, Cavalli G. et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: A single-centre retrospective cohort study. Eur J Intern Med 2020; 76: 43-49
    CrossrefPubMedSearch in Google Scholar
  • 13 Canziani LM, Trovati S, Brunetta E. et al. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. J Autoimmun 2020; 114: 102511
    CrossrefPubMedSearch in Google Scholar
  • 14 Capra R, De Rossi N, Mattioli F. et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med 2020; 76: 31-35
    CrossrefPubMedSearch in Google Scholar
  • 15 Chilimuri S, Sun H, Alemam A. et al. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study. J Clin Pharm Ther 2020;
    CrossrefPubMedSearch in Google Scholar
  • 16 Colaneri M, Bogliolo L, Valsecchi P. et al. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms 2020; 8: 695
    CrossrefPubMedSearch in Google Scholar
  • 17 De Rossi N, Scarpazza C, Filippini C. et al. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. EClinicalMedicine 2020; 100459
    CrossrefPubMedSearch in Google Scholar
  • 18 Eimer J, Vesterbacka J, Svensson AK. et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: A retrospective cohort study. J Intern Med 2020; 10.1111/joim.13162
    CrossrefPubMedSearch in Google Scholar
  • 19 Enzmann MO, Erickson MP, Grindeland CJ. et al. Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas. Epidemiol Infect 22.06.2020; 148: e124
    CrossrefPubMedSearch in Google Scholar
  • 20 Gokhale Y, Mehta R, Kulkami U. et al. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: A retrospective cohort study with follow-up from Mumbai, India. Research Square 2020;
    CrossrefPubMedSearch in Google Scholar
  • 21 Guaraldi G, Meschiari M, Cozzi-Lepri A. et al. Tocilizumab in patients with severe COVID-19: A retrospective cohort study. Lancet Rheumatol 2020;
    CrossrefPubMedSearch in Google Scholar
  • 22 Gupta S, Wang W, Hayek SS. et al. STOP-COVID Investigators. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Intern Med 2020; e206252
    CrossrefPubMedSearch in Google Scholar
  • 23 Hermine O, Mariette X, Tharaux PL. et al. CORIMUNO-19 Collaborative Group Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med 2020; e206820
    CrossrefPubMedSearch in Google Scholar
  • 24 Holt GE, Batra M, Murthi M. et al. Lack of tocilizumab effect on mortality in COVID19 patients. Sci Rep 2020; 10: 17100
    CrossrefPubMedSearch in Google Scholar
  • 25 Ip A, Berry DA, Hansen E. et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients – An observational study. medRxiv 2020;
    CrossrefPubMedSearch in Google Scholar
  • 26 Kewan T, Covut F, Al-Jaghbeer MJ. et al. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. EClinicalMedicine 2020; 24: 100418
    CrossrefPubMedSearch in Google Scholar
  • 27 Klopfenstein T, Zayet S, Lohse A. et al. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis 2020; 99: 491-495
    CrossrefPubMedSearch in Google Scholar
  • 28 Lengnan X, Xin L, Yangwei Z. et al. Tocilizumab May be a key in therapy for cytokine release syndrome in older patients with severe symptoms of COVID-19. Research Square 2020;
    CrossrefPubMedSearch in Google Scholar
  • 29 Masiá M, Fernández-González M, Padilla S. et al. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study. EBioMedicine 2020; 60: 102999
    CrossrefPubMedSearch in Google Scholar
  • 30 Martínez-Sanz J, Muriel A, Ron R. et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: A multicentre cohort study. Clin Microbiol Infect 2020; 20: 30573-30575
    CrossrefPubMedSearch in Google Scholar
  • 31 Menzella F, Fontana M, Salvarani C. et al. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care 2020; 24: 589
    CrossrefPubMedSearch in Google Scholar
  • 32 Mikulska M, Nicolini LA, Signori A. et al. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. PLoS One 2020; 15: e0237831
    CrossrefPubMedSearch in Google Scholar
  • 33 Moiseev S, Avdeev S, Tao E. et al. Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study. Ann Rheum Dis 2020;
    CrossrefPubMedSearch in Google Scholar
  • 34 Moreno-Pérez O, Andres M, Leon-Ramirez JM. et al. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. J Autoimmun 2020; 114: 102523
    CrossrefPubMedSearch in Google Scholar
  • 35 Perrone F, Piccirillo MC, Ascierto PA. et al. TOCIVID-19 investigators, Italy. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med 2020; 18: 405
    CrossrefPubMedSearch in Google Scholar
  • 36 Potere N, Di Nisio M, Cibelli D. et al. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study. Ann Rheum Dis 2020; annrheumdis-2020-218243
    CrossrefPubMedSearch in Google Scholar
  • 37 Price CC, Altice FL, Shyr Y. et al. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest 2020; 158: 1397-1408
    CrossrefPubMedSearch in Google Scholar
  • 38 Rodríguez-Baño J, Pachón J, Carratalà J. et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: A multicentre cohort study (SAM-COVID-19). Clin Microbiol Infect 2020; S1198-743X 20: 30492-30494
    CrossrefPubMedSearch in Google Scholar
  • 39 Rojas-Marte GR, Khalid M, Mukhtar O. et al. Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case- Controlled Study QJM. 2020; hcaa206
    CrossrefPubMedSearch in Google Scholar
  • 40 Roomi S, Ullah W, Ahmed F. et al. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review. J Med Internet Res 2020; 22: e21758
    CrossrefPubMedSearch in Google Scholar
  • 41 Rosas I, Brau N, Waters M. et al. Tocilizumab in Hospitalized Patients with COVID-19 Pneumonia. medRxiv 2020;
    CrossrefPubMedSearch in Google Scholar
  • 42 Rossi B, Nguyen LS, Zimmermann P. et al. Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study. Pharmaceuticals (Basel) 2020; 13: 317
    CrossrefPubMedSearch in Google Scholar
  • 43 Roumier M, Paule R, Groh M. et al. Interleukin-6 blockade for severe COVID-19. medRxiv 2020;
    CrossrefPubMedSearch in Google Scholar
  • 44 Ruiz-Antoran B, Sancho-Lopez A, Torres F. et al. Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: A Spanish, multicenter, cohort study. medRxiv 2020;
    CrossrefPubMedSearch in Google Scholar
  • 45 Salama C, Han J, Yau L. et al. Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia. medRxiv 2020;
    CrossrefPubMedSearch in Google Scholar
  • 46 Salvarani C, Dolci G, Massari M. et al RCT-TCZ-COVID-19 Study Group. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med 2020; e206615
    CrossrefPubMedSearch in Google Scholar
  • 47 Somers EC, Eschenauer GA, Troost JP. et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020; ciaa954
    CrossrefPubMedSearch in Google Scholar
  • 48 Stone JH, Frigault MJ, Serling-Boyd NJ. et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med 2020;
    CrossrefPubMedSearch in Google Scholar
  • 49 Wang D, Fu B, Peng Z. et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: A randomized, controlled, open-label, multicenter trial. SSRN 2020;
    CrossrefPubMedSearch in Google Scholar
  • 50 Leisman DE, Ronner L, Pinotti R. et al. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med 2020; 16 S2213-2600(20)30404-5
    CrossrefPubMedSearch in Google Scholar